BRITISH JOURNAL OF HAEMATOLOGY

Scope & Guideline

Transforming Hematology Through Rigorous Research

Introduction

Explore the comprehensive scope of BRITISH JOURNAL OF HAEMATOLOGY through our detailed guidelines, including its aims and scope. Stay updated with trending and emerging topics, and delve into declining areas to understand shifts in academic interest. Our guidelines also showcase highly cited topics, featuring influential research making a significant impact. Additionally, discover the latest published papers and those with high citation counts, offering a snapshot of current scholarly conversations. Use these guidelines to explore BRITISH JOURNAL OF HAEMATOLOGY in depth and align your research initiatives with current academic trends.
LanguageEnglish
ISSN0007-1048
PublisherWILEY
Support Open AccessNo
CountryUnited Kingdom
TypeJournal
Convergefrom 1955 to 2024
AbbreviationBRIT J HAEMATOL / Br. J. Haematol.
Frequency23 issues/year
Time To First Decision-
Time To Acceptance-
Acceptance Rate-
Home Page-
Address111 RIVER ST, HOBOKEN 07030-5774, NJ

Aims and Scopes

The British Journal of Haematology aims to publish high-quality research that enhances the understanding and treatment of blood disorders, including various leukaemias, lymphomas, myelomas, and other haematological conditions. The journal encompasses a wide range of topics from basic research to clinical applications, providing an essential platform for disseminating new findings and therapeutic strategies.
  1. Clinical Trials and Treatment Efficacy:
    The journal frequently publishes results from clinical trials and observational studies that assess the efficacy and safety of new treatments for haematological malignancies, including novel agents like CAR T-cell therapies, targeted therapies, and immunotherapies.
  2. Transfusion Medicine and Blood Disorders:
    Research on transfusion practices, complications, and management of blood disorders such as sickle cell disease, thalassaemia, and immune thrombocytopenia is a core focus area, addressing both clinical and logistical aspects of transfusion medicine.
  3. Molecular and Genetic Insights:
    The journal emphasizes studies that explore the molecular and genetic basis of haematological diseases, including the impact of specific mutations on prognosis and treatment response, integrating genomics with clinical outcomes.
  4. Patient-Centered Outcomes:
    There is a strong emphasis on patient-reported outcomes and quality of life assessments in patients with haematological conditions, highlighting the importance of treatment impact on patients' daily lives.
  5. Guidelines and Best Practices:
    The journal serves as a platform for disseminating guidelines and consensus statements from leading haematology societies, ensuring that practitioners have access to the latest recommendations for diagnosis and management.
The British Journal of Haematology is at the forefront of emerging trends in haematology research, reflecting advancements in technology, therapy, and patient care. Recent publications highlight several key themes that are gaining traction within the field.
  1. Novel Immunotherapies and CAR T-Cell Therapies:
    There is a growing body of research focused on innovative immunotherapies, particularly CAR T-cell therapies, which are being extensively studied for their efficacy in treating various haematological malignancies.
  2. Real-World Data and Observational Studies:
    An increasing number of publications emphasize the importance of real-world evidence and observational studies, providing insights into treatment effectiveness and patient outcomes in everyday clinical settings.
  3. Genomic and Precision Medicine:
    Research into genomic profiling and precision medicine is on the rise, with studies exploring how genetic mutations and biomarkers can inform tailored treatment approaches for individual patients.
  4. Impact of COVID-19 on Haematology Patients:
    The journal has seen a surge in studies assessing the impact of COVID-19 on patients with haematological conditions, including the effects on treatment protocols and patient outcomes.
  5. Patient-Centric Research and Quality of Life Studies:
    There is an emerging trend towards research that prioritizes patient perspectives, including quality of life assessments and patient-reported outcomes, recognizing the importance of holistic care in managing haematological diseases.

Declining or Waning

While the British Journal of Haematology continues to cover a broad range of topics, certain areas of research have seen a decline in focus over the years. This may reflect shifts in clinical priorities or the completion of research cycles in these domains.
  1. Traditional Chemotherapy Approaches:
    There has been a noticeable decline in publications focused solely on traditional chemotherapy regimens for haematological malignancies, as the field increasingly shifts towards targeted therapies and immunotherapies that promise improved outcomes.
  2. Longitudinal Studies of Established Therapies:
    Research on the long-term outcomes of established therapies such as older chemotherapeutic agents has decreased, likely due to the emergence of new treatment modalities that attract more research interest.
  3. Generalized Studies Without Specific Focus:
    There appears to be less emphasis on broad, generalized studies that do not target specific haematological conditions or interventions, as the field gravitates towards more precise and targeted research.
  4. Classic Transfusion Practices:
    Although transfusion medicine remains a significant area of focus, the exploration of classic transfusion practices is waning, with more attention being given to innovative transfusion strategies and technologies.
  5. Historical Perspectives on Haematology:
    Papers focusing on historical aspects of haematology or retrospective analyses of outdated treatments are becoming less common, indicating a shift towards contemporary research that addresses current challenges.

Similar Journals

Blood Cancer Journal

Transforming insights into impactful treatments.
Publisher: SPRINGERNATUREISSN: 2044-5385Frequency: 1 issue/year

Blood Cancer Journal, published by SPRINGERNATURE, is a leading open-access journal that has been at the forefront of hematology and oncology research since its inception in 2011. With an impressive impact factor and a commitment to disseminating high-quality research, it holds a prestigious Q1 ranking in both hematology and oncology categories as of 2023. The journal is dedicated to publishing innovative studies, comprehensive reviews, and insightful commentaries that advance our understanding of blood cancers, making it an essential resource for researchers, healthcare professionals, and students in the field. Its open-access model ensures that groundbreaking research is accessible to a global audience, promoting collaborative efforts to enhance treatment methodologies and patient outcomes. With a strong reputation illustrated by its Scopus rankings—8th in hematology and 30th in oncology—Blood Cancer Journal exemplifies excellence and leadership in the ever-evolving landscape of cancer research.

EUROPEAN JOURNAL OF HAEMATOLOGY

Advancing Hematology Research for a Healthier Tomorrow
Publisher: WILEYISSN: 0902-4441Frequency: 12 issues/year

EUROPEAN JOURNAL OF HAEMATOLOGY, published by Wiley, serves as a vital resource for experts in the field of hematology, focusing on the latest advancements in blood disorders and therapies. With an ISSN of 0902-4441 and an E-ISSN of 1600-0609, this esteemed journal has been disseminating knowledge since 1986 and continues to thrive, converging its visionary approach through to 2024. Notably, it holds a distinguished Q2 ranking in Hematology and an impressive Q1 ranking in the broader category of Medicine (miscellaneous) as of 2023, highlighting its significant contribution to the scientific community. With a Scopus rank of #45/137 and a 67th percentile in the field, the journal is recognized for its rigorous peer-reviewed research, making it an indispensable publication for researchers, practitioners, and students aiming to stay at the forefront of hematological studies. Though not an open-access journal, it ensures broad accessibility to critical findings via its subscription model, thus fostering an informed and globally engaged audience.

Turkish Journal of Hematology

Unveiling the latest breakthroughs in blood health and treatment.
Publisher: GALENOS PUBL HOUSEISSN: 1300-7777Frequency: 4 issues/year

Turkish Journal of Hematology is an esteemed publication dedicated to advancing the field of hematology, producing influential research since its inception in 1999 under the auspices of GALENOS PUBL HOUSE. With an Open Access model, it facilitates widespread dissemination of knowledge, allowing researchers, clinicians, and students to stay abreast of the latest developments in blood disorders and treatments. With an ISSN of 1300-7777 and an E-ISSN of 1308-5263, the journal holds a commendable position in the academic community, evidenced by its 2023 Q3 ranking within the hematology category and its standing at #80 out of 137 in the Scopus database, placing it in the 41st percentile. Covering a wide scope of topics within hematology, this journal serves as a critical resource for disseminating innovative research and clinical practices pertinent to the ongoing challenges faced in this vital area of medicine. With its continuous publication until 2024, Turkish Journal of Hematology remains a beacon for enhancing the understanding and treatment of hematological conditions within the Turkish and global medical communities.

Transfusionsmedizin

Connecting clinicians and researchers in transfusion medicine.
Publisher: GEORG THIEME VERLAG KGISSN: 2191-8805Frequency: 4 issues/year

Transfusionsmedizin is a premier journal dedicated to the field of transfusion medicine, published by the renowned GEORG THIEME VERLAG KG. With an ISSN of 2191-8805 and an E-ISSN of 2191-8813, this journal serves as a vital platform for disseminating cutting-edge research and clinical advancements in blood transfusion practices. Although it operates under a subscription model, the journal is committed to high-quality peer-reviewed content that addresses contemporary challenges and innovations in transfusion therapy. By fostering dialogue among researchers, clinicians, and students, Transfusionsmedizin aims to advance patient care and enhance the safety and efficacy of transfusion practices globally. Its contributions are essential for professionals engaged in transfusion science, hematology, and related medical fields, solidifying its reputation as a critical resource for staying abreast of the latest developments in transfusion research.

Experimental Hematology & Oncology

Driving Progress in Blood Health and Cancer Solutions
Publisher: BMCISSN: Frequency: 1 issue/year

Experimental Hematology & Oncology is a premier journal published by BMC, dedicated to advancing knowledge in the fields of hematology, oncology, and cancer research. Since its inception in 2012, this Open Access journal has emerged as a vital resource for researchers and healthcare professionals, fostering the dissemination of high-quality research that enhances our understanding of blood disorders and malignancies. With impressive rankings in Quarters 1 of key categories including Cancer Research, Hematology, and Oncology, it holds significant prestige, evidenced by its Scopus rankings: #42/404 in Medicine (Oncology) and #17/137 in Medicine (Hematology). The journal aims to publish cutting-edge studies, reviews, and perspectives that contribute to the evolution of therapeutic strategies and innovative treatment modalities. Researchers and practitioners alike will find this journal indispensable for staying at the forefront of breakthroughs in hematological and oncological research.

Blood Science

Enhancing Patient Care Through Scholarly Insights
Publisher: LIPPINCOTT WILLIAMS & WILKINSISSN: 2543-6368Frequency:

Blood Science is a distinguished peer-reviewed journal published by Lippincott Williams & Wilkins, focusing on the dynamic field of hematology. Since its inception, the journal has aimed to disseminate high-quality research and innovative findings that contribute to our understanding of blood-related health issues. With the ISSN 2543-6368, it offers a platform for academic discussions and breakthroughs in various subfields including hematopathology, blood disorders, and transfusion medicine. As of 2023, Blood Science is ranked in the third quartile (Q3) within the hematology category, indicating a burgeoning influence among its peers, with a Scopus rank of #101 out of 137 journals, placing it in the 26th percentile. Although it is not an open-access journal, it provides essential insights and valuable data for researchers, healthcare professionals, and students alike, enhancing the collective knowledge and practices in hematology. With a publication period spanning from 2019 to 2024, Blood Science remains committed to fostering the advancement of blood science research and enhancing patient care methodologies.

HemaSphere

Elevating hematology with high-impact findings.
Publisher: WILEYISSN: Frequency: 12 issues/year

HemaSphere, published by WILEY, stands at the forefront of hematology research, offering a vital platform for the dissemination of cutting-edge findings in the field. Since its inception in 2017 and official transition to Open Access in 2018, the journal has positioned itself as a leading conduit for high-impact research, maintaining a prestigious Q1 quartile ranking in the Hematology category as of 2023. Addressed in the United States at 111 River St, Hoboken, NJ, HemaSphere aims to foster a global dialogue among researchers, clinicians, and students by providing unrestricted access to high-quality content that encompasses clinical and experimental advancements. With an array of engaging articles, reviews, and commentaries, HemaSphere contributes significantly to the advancement of hematology, ensuring that critical knowledge is readily accessible to enhance patient care and innovative research. To explore the latest developments and breakthroughs in this dynamic field, we invite scholars, professionals, and students to engage with HemaSphere and elevate their understanding of hematologic science.

TRANSFUSION MEDICINE AND HEMOTHERAPY

Empowering innovation in hematology and transfusion medicine.
Publisher: KARGERISSN: 1660-3796Frequency: 6 issues/year

TRANSFUSION MEDICINE AND HEMOTHERAPY, published by KARGER, is a prominent journal dedicated to advancing the fields of hematology and transfusion medicine. With an ISSN of 1660-3796 and E-ISSN 1660-3818, this esteemed journal has been a valuable resource for researchers and clinicians since its inception in 1973, with significant publication phases continuing into 2024. It currently holds a Q2 ranking in Hematology and a Q3 ranking in Immunology and Allergy, reflecting its impact and relevance in these critical fields. The journal features original articles, reviews, and clinical studies, presenting cutting-edge research that aids in the development of effective therapies and enhances patient care. Open access options are available, ensuring that crucial findings are accessible to a broad audience. As an important platform for dialogue and advancement in transfusion science, TRANSFUSION MEDICINE AND HEMOTHERAPY supports the global health community's efforts to improve treatment outcomes and foster innovation in medical practices.

Egyptian Journal of Haematology

Shaping the Landscape of Hematology in the Middle East
Publisher: WOLTERS KLUWER MEDKNOW PUBLICATIONSISSN: 1110-1067Frequency: 4 issues/year

The Egyptian Journal of Haematology, published by WOLTERS KLUWER MEDKNOW PUBLICATIONS, stands as a pivotal resource in the field of hematology, particularly within the context of Egypt and the broader Middle Eastern region. This journal is dedicated to disseminating high-quality research that explores the latest advancements in blood disorders, hematologic malignancies, and transfusion medicine. With a focus on original research, case studies, and reviews, it aims to provide a comprehensive platform for hematologists, researchers, and healthcare professionals to enhance their understanding and management of hematological conditions. Although it is not an open-access journal, the rigorous peer-review process ensures that only the most impactful studies are published, contributing to the journal's reputation in the academic community. The Egyptian Journal of Haematology serves as an essential tool for advancing knowledge, improving clinical outcomes, and fostering collaboration among experts in the field.

Blood Research

Transforming Knowledge into Clinical Excellence
Publisher: SPRINGERISSN: 2287-979XFrequency: 4 issues/year

Blood Research, published by SPRINGER, is a premier journal dedicated to the multifaceted realm of hematology, serving as a crucial platform for disseminating innovative research findings and advancements in the diagnosis and treatment of blood-related disorders. With an ISSN of 2287-979X and an E-ISSN of 2288-0011, this journal is recognized for its commitment to scholarly excellence and impact in the field, currently holding a reputable Q2 ranking in the Hematology category as per the 2023 metrics. The journal spans from 2013 to 2024, providing a broad archive of quality research that is vital for researchers, healthcare professionals, and students alike. Although it is not an Open Access journal, it offers insightful contributions that enhance the understanding of hematological science, fostering the exchange of knowledge crucial for advancing patient care and clinical practices globally. The journal’s performance is underscored by its Scopus ranking in the 46th percentile, reflecting its significant role in the ongoing discourse in hematology.